Trials / Unknown
UnknownNCT03049774
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
A Retrospective Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include May 8th of 2008 to december 31st of 2016.
Conditions
Timeline
- Start date
- 2017-02-28
- Primary completion
- 2017-08-01
- Completion
- 2017-12-01
- First posted
- 2017-02-10
- Last updated
- 2017-02-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03049774. Inclusion in this directory is not an endorsement.